Cancer Expanded Access Plans Need Focus On Data Collection – FDA’s Pazdur
Executive Summary
Expanded access programs for cancer products should be limited in scope to gather data on use in patients with refractory disease, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said at the American Society of Clinical Oncology annual meeting in Orlando May 18
You may also be interested in...
Iressa Expanded Access Could Have Been Designed To Bolster Efficacy
AstraZeneca's expanded access program for Iressa could have been designed to bolster efficacy data from pivotal trials, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested
FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input
FDA has renewed development of a guidance on the use of quality of life claims in drug labeling and promotional materials after gathering input from industry
Iressa Expanded Access Could Have Been Designed To Bolster Efficacy
AstraZeneca's expanded access program for Iressa could have been designed to bolster efficacy data from pivotal trials, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested